Information and Resources
PCF reports that U.S. Food and Drug Administration has approved Abiraterone + Prednisone combination for men with metastatic high-risk castration-sensitive prostate cancer (CSPC). The approval is based on the results of the LATITUDE study.
Read more on pcf.org here
By Ravi A. Madan, MD, and William L. Dahut, MD
Although immunotherapies are poised to permanently reshape treatment for bladder and kidney cancers, immune-based therapeutics research in prostate cancer has stagnated. There is immunotherapy available for prostate cancer, however, the delayed effects of treatment and the rare effect on prostate-specific antigen (PSA) levels have generated less enthusiasm compared with the rapid and sustained responses in some patients with bladder and kidney cancers who have been treated with immune checkpoint inhibitors. In addition, recent negative results of some trials have raised more concerns about the lack of potential for immunotherapy in prostate cancer. Nonetheless, several ongoing studies of immune checkpoint inhibitor combinations are potentially defining a course for immunotherapy development.
Read the article here
Metastatic prostate cancer can turn on a dime. For too long, a sudden shift in the disease has meant bad news. But now, more and more men are seeing a sudden turn in the right direction. Jeff Finerman is one of them.
To read more, click HERE.
FDA has approved the FoundationOne CDx (F1CDx) cancer biomarker assay concurrently with a decision from the Centers for Medicare & Medicaid Services (CMS) to provide insurance coverage for the next-generation sequencing (NGS)-based in vitro diagnostic (IVD) test.
FDA Approves Foundation Medicine’s FoundationOne CDx™, the First and Only Comprehensive Genomic Profiling Test for All Solid Tumors Incorporating Multiple Companion Diagnostics.
Read more about it here
US Too Prostate Cancer Panel Discussion and Webcast on Advanced Prostate Cancer
Watch the recording here
Dr. Mark Scholz participated in a tumor board session with a discussion of Prostate Cancer Cases at El Camino Hospital in November 2017.
Participants included:
View the recording of the event here
The purpose of this short eBook is to provide men facing prostate cancer with a lot of up-to-date information in a compact format.
The information and opinions provided in this book are not specific medical advice for any individual. It should not substitute for medical advice from a healthcare professional. The author is not a medical doctor. The reader is advised that any information or opinions expressed or implied in this book are those of a layman and should not be acted upon without the consent of a licensed physician. This book is not meant to be used, nor should it be used, to diagnose or treat any medical condition. For diagnosis or treatment of any medical problem, consult your own physician.
Download the pdf ebook here.
In line with previously reported data, the US Food and Drug Administration (FDA) approved the used of a 20 mg/ml dose of cabazitaxel (Jevtana) in the treatment of men with metastatic, castration-resistant prostate cancer (mCRPC). However, the use of this dose of cabazitaxel is currently approved only for men who have previously been treated with docetaxel-based chemotherapy.
Read more here on Prostate Cancer InfoLink
Apparently, late yesterday, Barvarian Nordic announced that Prostvac has failed to show efficacy in the Phase III PROSPECT trial of the treatment of men with metastatic, castration-resistant prostate cancer (mCRPC).
Click here for Barvarian Nordic’s media release
Read more here on Prostate Cancer InfoLink
The U.S. Food and Drug Administration today granted accelerated approval to a treatment for patients whose cancers have a specific genetic feature (biomarker). This is the first time the agency has approved a cancer treatment based on a common biomarker rather than the location in the body where the tumor originated.
Read more on fda.gov